Pangea Bio

The company's core is its proprietary AI discovery engine, PangeAI™, which utilizes computational metabolomics and generative AI to identify neuroactive molecules from natural sources like plants and fungi. This platform analyzes data from medicinal species with a history of traditional use to find compounds with existing signals of human efficacy and safety. Pangea's approach aims to accelerate the drug discovery process and reduce the high failure rates and costs typical in pharmaceutical development. The PangeAI™ platform has integrated over half a billion data points related to the connections between plants and human health.

Pangea Bio's business model focuses on creating a pipeline of drug candidates for central nervous system (CNS) disorders. The company's lead R&D program centers on a proprietary small molecule that targets the TrkB receptor, a key regulator of neuroplasticity, which has shown potential in models for conditions like schizophrenia, Parkinson's, and Alzheimer's disease. This lead candidate is expected to enter Phase 1 clinical trials in early 2025. The company operates out of London and Berlin with a team of over 25 people. It has raised $15 million in funding and secured several non-dilutive grants. In May 2024, Pangea Bio became a certified B Corporation, reflecting a commitment to social and environmental performance.